The ReadoutCaution on Sage & what’s next for OrbiMed? By Damian Garde and Meghana Keshavan Dec. 11, 2017 Reprints Alex Hogan/STAT The Readout for December 11, 2017 About the Authors Reprints Damian Garde National Biotech Reporter Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast. [email protected] @damiangarde Meghana Keshavan Biotech Correspondent Meghana Keshavan covers biotech and contributes to The Readout newsletter. [email protected] @megkesh
The Readout Meghana Keshavan Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
The Readout Damian Garde Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
Health Tech Mohana Ravindranath and Casey Ross STAT Plus: Cerebral and other telehealth startups face new legal and regulatory challenges over ad models
Health Tech Brittany Trang and Casey Ross STAT Plus: ‘We’re getting much more aggressive’: Microsoft’s Nuance adds GPT-4 AI to its medical note-taking tool
A STAT Investigation Casey Ross and Bob Herman STAT Plus: Denied by AI: How Medicare Advantage plans use algorithms to cut off care for seniors in need
